Urszula Częścik^1,2,#, Martyna Gryglas³, Arkadiusz Szterk⁴, Sylwia Flis^3,#,*

Oncology Research, Vol.34, No.2, 2026, DOI:10.32604/or.2025.067449 - 19 January 2026

Abstract Colorectal cancer (CRC) is the third most common malignancy worldwide and the second leading cause of cancer-related deaths, accounting for approximately 10% of all cancer cases. By 2050, CRC incidence is expected to rise substantially, driven by population aging and greater exposure to risk factors in developing countries. Despite advances in medicine and pharmacy, the effectiveness of available treatments remains limited, underscoring the urgent need for innovative therapeutic strategies. This review summarizes and critically evaluates currently available CRC therapies and explores new emerging directions. Particular attention is given to the role of immunotherapy, targeted therapies,… More >

Yi Feng^1,#, Haoxin Yang², Guicai Liang¹, Jun Chen³, Tao Li¹, Yingjuan Wang⁴, Jilin Chang¹, Yan Li³, Meng Yang¹, Xilong Zhou¹, Zhiqiang Wang^5,*, Chunlei Ge^1,*

Oncology Research, Vol.33, No.12, pp. 3801-3836, 2025, DOI:10.32604/or.2025.067824 - 27 November 2025

Abstract Immune checkpoint inhibitor (ICI) has limited efficacy in the treatment of immune “cold” tumors. Due to insufficient T cell infiltration and heterogeneous programmed death ligand 1 (PD-L1) expression, the ORR is only 5%–8% compared with 30%–40% of “hot” tumors. This article reviews the synergistic mechanism, clinical efficacy and optimization strategy of oncolytic virus (OVs) combined with ICIs in the treatment of refractory malignant tumors. Systematic analysis of mechanistic interactions across tumor types and clinical trial data demonstrates that OVs transform the immunosuppressive microenvironment by inducing immunogenic cell death and activating innate immunity. Concurrently, ICIs enhance… More >

Jianan Lei^*, Zhuona Ni, Ruidi Zhang

Oncology Research, Vol.33, No.11, pp. 3347-3373, 2025, DOI:10.32604/or.2025.067445 - 22 October 2025

Abstract This review aims to explore the development, challenges, and future directions of UCAR cell therapy as a scalable alternative to autologous CAR-T for cancer treatment. Consequently, limitations of autologous CAR-T, including long production, variable quality, and cost, drive off-the-shelf UCAR development to standardize manufacturing and improve access. Current UCAR-T cell strategies focus on mitigating the risks of graft-vs.-host disease and host-vs.-graft rejection through advanced gene editing technologies, including clustered regularly interspaced short palindromic repeat-associated system Cas9-mediated knockout of the T cell receptor, human leukocyte antigen, and cluster of differentiation 52 (CD52). Beyond conventional T cells, cell… More >

CHUCHU ZHANG^1,#, YING LIU^2,#, ZEHUI CHEN¹, YI LIU³, QIYUAN MAO⁴, GE ZHANG⁵, HONGSHENG LIN⁴, JIABIN ZHENG^6,*, HAIYAN LI^1,*

Oncology Research, Vol.33, No.6, pp. 1437-1458, 2025, DOI:10.32604/or.2025.059290 - 29 May 2025

Abstract Objectives: Decades of clinical and fundamental research advancements in oncology have led to significant breakthroughs such as early screening, targeted therapies, and immunotherapy, contributing to reduced mortality rates in cancer patients. Despite these achievements, cancer continues to be a major public health challenge. This study employs bibliometric techniques to visually analyze the English literature on cancer prevention, screening, diagnosis, treatment, and rehabilitation. Methods: We systematically reviewed publications from 01 March 2014, to 01 March 2024, indexed in the Web of Science core collection. Tools such as VOSviewer Version 1.6.20 is characterized by its core idea… More > Graphic Abstract

GIULIANO BERNAL^*, GISELA AQUEA, SEBASTIÁN RAMÍREZ-RIVERA

Oncology Research, Vol.33, No.4, pp. 759-779, 2025, DOI:10.32604/or.2024.057019 - 19 March 2025

Abstract Cancer remains one of the leading causes of death in the world, with more than 9 million deaths in 2022, a number that continues to rise. This highlights the urgent need for the development of new drugs, with enhanced antitumor capabilities and fewer side effects. Metal-based drugs have been used in clinical practice since the late 1970s, beginning with the introduction of cisplatin. Later, two additional platinum-based molecules, carboplatin, and oxaliplatin, were introduced, and all three continue to be widely used in the treatment of various cancers. However, despite their significant anticancer activity, the undesirable… More > Graphic Abstract

LISANNE K.A. NEIJENHUIS^1,2,3,#, LEUTA L. NAUMANN^4,#, SONIA A.M. FERKEL¹, SAMUEL J.S. RUBIN¹, STEPHAN ROGALLA^1,*

Oncology Research, Vol.32, No.7, pp. 1163-1172, 2024, DOI:10.32604/or.2024.050907 - 20 June 2024

Abstract Background: Osteosarcoma is the most common malignant primary bone tumor. The prognosis for patients with disseminated disease remains very poor despite recent advancements in chemotherapy. Moreover, current treatment regimens bear a significant risk of serious side effects. Thus, there is an unmet clinical need for effective therapies with improved safety profiles. Taurolidine is an antibacterial agent that has been shown to induce cell death in different types of cancer cell lines. Methods: In this study, we examined both the antineoplastic and antiangiogenic effects of taurolidine in animal models of osteosarcoma. K7M2 murine osteosarcoma cells were… More >

QIUQIANG CHEN^1,*, XUEJUN GUO², WENXUE MA^3,*

Oncology Research, Vol.32, No.1, pp. 49-60, 2024, DOI:10.32604/or.2023.042383 - 15 November 2023

Abstract Cancer immunotherapy has emerged as a promising strategy for the treatment of cancer, with the tumor microenvironment (TME) playing a pivotal role in modulating the immune response. CD47, a cell surface protein, has been identified as a crucial regulator of the TME and a potential therapeutic target for cancer therapy. However, the precise functions and implications of CD47 in the TME during immunotherapy for cancer patients remain incompletely understood. This comprehensive review aims to provide an overview of CD47’s multifaced role in TME regulation and immune evasion, elucidating its impact on various types of immunotherapy… More > Graphic Abstract

ABHISHEK WAHI¹, MAMTA BISHNOI², NEHA RAINA¹, MEGHNA AMRITA SINGH¹, PIYUSH VERMA¹, PIYUSH KUMAR GUPTA^3,4, GINPREET KAUR⁵, HARDEEP SINGH TULI^6,*, MADHU GUPTA^1,*

Oncology Research, Vol.32, No.1, pp. 19-47, 2024, DOI:10.32604/or.2023.042228 - 15 November 2023

Abstract Cancer is a leading cause of death globally, with limited treatment options and several limitations. Chemotherapeutic agents often result in toxicity which long-term conventional treatment. Phytochemicals are natural constituents that are more effective in treating various diseases with less toxicity than the chemotherapeutic agents providing alternative therapeutic approaches to minimize the resistance. These phytoconstituents act in several ways and deliver optimum effectiveness against cancer. Nevertheless, the effectiveness of phyto-formulations in the management of cancers may be constrained due to challenges related to inadequate solubility, bioavailability, and stability. Nanotechnology presents a promising avenue for transforming current… More > Graphic Abstract

DHANYA K. NAMBIAR¹, DEEPALI MISHRA², RANA P. SINGH^2,3,*

Oncology Research, Vol.31, No.4, pp. 405-421, 2023, DOI:10.32604/or.2023.028310 - 25 June 2023

Abstract Ionizing radiation is frequently used to treat solid tumors, as it causes DNA damage and kill cancer cells. However, damaged DNA is repaired involving poly-(ADP-ribose) polymerase-1 (PARP-1) causing resistance to radiation therapy. Thus, PARP-1 represents an important target in multiple cancer types, including prostate cancer. PARP is a nuclear enzyme essential for single-strand DNA breaks repair. Inhibiting PARP-1 is lethal in a wide range of cancer cells that lack the homologous recombination repair (HR) pathway. This article provides a concise and simplified overview of the development of PARP inhibitors in the laboratory and their clinical More > Graphic Abstract

Kassem S. Faraj¹, Weslyn D. Bunn², Victoria S. Edmonds², Mark D Tyson¹

Canadian Journal of Urology, Vol.29, No.5, pp. 11284-11290, 2022

Abstract Introduction: A comprehensive analysis on outcomes in the perioperative and pathological setting in patients with a prior diagnosis of prostate cancer has not been performed. The objective of this study is to describe the effect of prior prostate cancer treatment on perioperative and pathological outcomes after cystectomy.
Materials and methods: This was a retrospective review of all male patients who underwent cystectomy at our institution from 01/01/2007-01/01/2020. Patients who were previously diagnosed and treated for prostate cancer were identified and outcomes were assessed.
Results: In 525 male patients, 132 (25.1%) had a diagnosis of prostate cancer prior to… More >